HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The primary goal of this phase I open label study is to determine the safety and tolerability
of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with
TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy
confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins